While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use a variety of methods, inc ...

AUSTIN, Texas, Nov. 12, 2024 /PRNewswire/ -- eHealth, Inc. (Nasdaq: EHTH), a leading private online health insurance marketplace, announced that Fran Soistman, Chief Executive Officer, will participate in a fireside chat format presentation at the UBS Global Healthcare Conference today on Tuesday, November 12th, 2024, at 4:15 p.m. Pacific Time.Interested investors can access the live audio webcast of the discussion on eHealth's Investor Relations website at https://ir.ehealthinsurance.com.About eHealth, Inc ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The news team covers various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] - Proactive has a presence in key finance and investing hubs with bureaus and studios located in major cities such as London, New York, and Sydney [2] Group 2 - The company utilizes technology to enhance workflows and has adopted automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [4]

Company Announcement - Avanos Medical, Inc. will have its interim CEO, Michael Greiner, participate in a fireside chat at the UBS 2024 Healthcare Conference on November 12 at approximately 2:45 p.m. Pacific Time [1] - A webcast of the conference presentation will be available on the Investors section of the Avanos Medical website and will be archived for future access [1] Company Overview - Avanos Medical, Inc. is a medical technology company headquartered in Alpharetta, Georgia, focused on delivering clinically superior medical device solutions [2] - The company addresses significant healthcare needs, including providing nutrition support for patients transitioning from hospital to home and reducing opioid use during recovery [2] - Avanos develops, manufactures, and markets recognized brands globally, holding leading market positions across multiple categories in its portfolio [2]

THOUSAND OAKS, Calif., Nov. 8, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 UBS Global Healthcare Conference at 10:15 a.m. PT on Wednesday, Nov. 13, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.The webcast, as with other selected presentations regarding developments in A ...

Company Overview - 89bio, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and cardiometabolic diseases [3] - The company is headquartered in San Francisco and is dedicated to creating best-in-class treatments for patients lacking optimal options [3] Key Developments - The company will participate in a fireside chat at the UBS Global Healthcare Conference on November 12, 2024, at 12:30 PM EST [1] - Management will also engage in one-on-one investor meetings during the conference [1] Product Pipeline - 89bio is currently in Phase 3 studies for its lead candidate, pegozafermin, targeting metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG) [3] - Pegozafermin is a fibroblast growth factor 21 (FGF21) analog utilizing unique glycoPEGylated technology to enhance biological activity through an extended half-life [3]

MARLBOROUGH, Mass., Nov. 5, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024. Nick Spadea-Anello, president, Electrophysiology, and Jon Monson, senior vice president, Investor Relations, will participate in a 35-minute question-and-answer session with the host analyst at approximately 7:15 a.m. PT / 10:15 a.m. ET. A live webcast and replay of the session will be accessible at htts://investors.bostonscie ...

PONTE VEDRA, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, ...

BEIJING, Oct. 31, 2024 /PRNewswire/ -- NaaS Technology Inc. (Nasdaq: NAAS) ("NaaS" or the "Company"), the first U.S.-listed EV charging service company in China, today announced that Mr. Steven Sim, Chief Financial Officer of NaaS, will be featured on UBS's Charging Industry Call Series on November 4, 2024.Event: UBS Charging Industry Call Series – "Charged Up: Inflection of Earnings"Moderator: Ms. Wei Shen, Head of China Auto Research, UBSFeatured Guest: Mr. Steven Sim, Chief Financial Officer of NaaSDate ...

Core Insights - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases [1][2] - The company will participate in a fireside chat at the UBS Global Healthcare Conference scheduled for November 11-14, 2024, in Rancho Palos Verdes, CA [1][2] Company Overview - Reviva's current pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [2] - The company has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries [2]